Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunocore Holdings Plc ADR (NQ: IMCR ) 39.78 +0.91 (+2.34%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 283,298 Open 38.80 Bid (Size) 36.09 (1) Ask (Size) 40.35 (1) Prev. Close 38.87 Today's Range 38.30 - 40.07 52wk Range 33.05 - 76.98 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Peeling Back The Layers: Exploring Immunocore Hldgs Through Analyst Insights July 10, 2024 Via Benzinga Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma June 18, 2024 From Immunocore Holdings plc Via GlobeNewswire Performance YTD -44.47% -44.47% 1 Month +13.27% +13.27% 3 Month -28.74% -28.74% 6 Month -44.69% -44.69% 1 Year -38.70% -38.70% More News Read More Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response June 01, 2024 From Immunocore Holdings plc Via GlobeNewswire Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 May 31, 2024 From Immunocore Holdings plc Via GlobeNewswire Analyst Expectations For Immunocore Hldgs's Future May 24, 2024 Via Benzinga Where Immunocore Hldgs Stands With Analysts April 29, 2024 Via Benzinga Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 03, 2024 Via Benzinga Immunocore to present at the Jefferies Global Healthcare Conference May 30, 2024 From Immunocore Holdings plc Via GlobeNewswire Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) April 11, 2024 Via Benzinga Key Takeaways From Immunocore Hldgs Analyst Ratings February 29, 2024 Via Benzinga Immunocore Hldgs's Earnings: A Preview February 27, 2024 Via Benzinga Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma May 29, 2024 From Immunocore Holdings plc Via GlobeNewswire Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session May 24, 2024 Via Benzinga IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024 May 08, 2024 Via InvestorPlace Immunocore reports first quarter financial results and provides a business update May 08, 2024 From Immunocore Holdings plc Via GlobeNewswire Immunocore announces upcoming presentation and posters at ASCO 2024 April 24, 2024 From Immunocore Holdings plc Via GlobeNewswire Immunocore to present at upcoming investor conferences April 04, 2024 From Immunocore Holdings Limited Via GlobeNewswire Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio March 13, 2024 Via InvestorPlace Immunocore presented two posters at CROI 2024 March 05, 2024 From Immunocore Holdings Limited Via GlobeNewswire Immunocore to present at upcoming investor conferences March 01, 2024 From Immunocore Holdings Limited Via GlobeNewswire Immunocore reports fourth quarter and full year 2023 financial results and provides a business update February 28, 2024 From Immunocore Holdings Limited Via GlobeNewswire Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial February 22, 2024 From Immunocore Holdings Limited Via GlobeNewswire Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024 February 21, 2024 From Immunocore Holdings Limited Via GlobeNewswire Immunocore Prices Upsized Convertible Senior Notes Offering January 30, 2024 From Immunocore Holdings Limited Via GlobeNewswire Immunocore Announces Proposed Convertible Senior Notes Offering January 29, 2024 From Immunocore Holdings Limited Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
